LIAN News and Press, LianBio From 08/11/22

LianBio press release ( NASDAQ: LIAN ): Q2 GAAP EPS of -$0.39 misses by $0.11 . For further details see: LianBio GAAP EPS of -$0.39 misses by $0.11

Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three additional registration-enabling programs to begin in China by y...

• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of mavacamten in China SHANGHAI, China and PRINCETON, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasda...

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. ( NASDAQ: NBTX ) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix ( NBTX ) plunged nearly 30% on above-average volume to reach an al...

SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in fires...

Cantor Fitzgerald initiated Lyra Therapeutics (NASDAQ:LYRA) with an overweight rating saying the company's pipeline is not appreciated enough. The firm has a $15 price target (~147% upside based on Monday's close). Analyst Louise Chen highlighted two candidates in particular, LYR-210 and LYR-...

The following slide deck was published by LianBio in conjunction with this event. For further details see: LianBio (LIAN) Investor Presentation - Slideshow

LianBio press release (NASDAQ:LIAN): Q1 GAAP EPS of -$0.26. Cash, cash equivalents, marketable securities and restricted cash at March 31, 2022 totaled $389.1 million compared to $403.2 million as of December 31, 2021, with runway through mid-2024. For further details see: Lia...

LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic...

Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in Chin...